Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1CNS 1

Conditions

Neoplasms 281Carcinoma, Non-Small-Cell Lung 251Leukemia, Myeloid, Acute 189Breast Neoplasms 151Melanoma 150Neoplasm Metastasis 148Multiple Myeloma 127Recurrence 123Colorectal Neoplasms 119Lymphoma, Non-Hodgkin 113Lymphoma 112Leukemia, Lymphocytic, Chronic, B-Cell 107Pancreatic Neoplasms 99Ovarian Neoplasms 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 91Leukemia 85Prostatic Neoplasms 83Lung Neoplasms 81Lymphoma, Large B-Cell, Diffuse 77Squamous Cell Carcinoma of Head and Neck 76Glioblastoma 73Carcinoma, Renal Cell 72Myelodysplastic Syndromes 67Lymphoma, Follicular 65Brain Neoplasms 60Lymphoma, Mantle-Cell 55Sarcoma 53Stomach Neoplasms 52Head and Neck Neoplasms 52Triple Negative Breast Neoplasms 49

Interventions

Dexamethasone 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Prolactinoma × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡